Recommendation of the President – Welireg (belzutifan)
On 17 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 197/2025 on the reimbursement of the medicinal product Welireg (belzutifan) under the drug program “Treatment of patients with Von Hippel-Lindau disease (ICD-10: Q85.8)”